Dashboard
High Management Efficiency with a high ROCE of 16.93%
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.81 times
The company has declared Positive results for the last 4 consecutive quarters
Stock is technically in a Mildly Bullish range
With ROCE of 16.5, it has a Expensive valuation with a 3.6 Enterprise value to Capital Employed
High Institutional Holdings at 35.58%
Stock DNA
Pharmaceuticals & Biotechnology
INR 22,084 Cr (Small Cap)
32.00
40
0.20%
-0.06
10.68%
3.34
Total Returns (Price + Dividend) 
Latest dividend: 1.75 per share ex-dividend date: Jul-30-2026
Risk Adjusted Returns v/s 
Returns Beta
News

Granules India Ltd is Rated Hold by MarketsMOJO
Granules India Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 28 September 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 13 November 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read More
Granules India Ltd is Rated Hold by MarketsMOJO
Granules India Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 28 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 November 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Granules India Ltd Valuation Shifts to Very Expensive Amid Strong Returns
Granules India Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has seen its valuation metrics shift markedly, moving from an expensive to a very expensive territory. Despite this, the company continues to deliver robust returns, outperforming the Sensex significantly over multiple time horizons. This article analyses the recent valuation changes, compares them with historical and peer averages, and assesses the implications for investors.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
10-Nov-2026 | Source : BSESchedule of Investor Meet
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
06-Nov-2026 | Source : BSETranscript of the Earnings Conference Call for Q2 and the half year of FY27
Change In Corporate Office Address Of Registrar And Share Transfer Agent
06-Nov-2026 | Source : BSEChange in Corporate Office Address of Registrar and Share Transfer Agent (RTA)
Corporate Actions 
No Upcoming Board Meetings
Granules India Ltd has declared 175% dividend, ex-date: 30 Jul 26
Granules India Ltd has announced 1:10 stock split, ex-date: 23 Mar 15
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 27 Schemes (4.26%)
Held by 247 FIIs (20.25%)
Krishna Prasad Chigurupati (21.85%)
Smallcap World Fund, Inc (4.54%)
17.94%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 5.63% vs 0.42% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 1.04% vs -10.72% in Jun 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 16.80% vs -1.31% in Sep 2024
Growth in half year ended Sep 2025 is 4.90% vs 54.58% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 18.60% vs -1.39% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 12.58% vs 26.78% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 19.73% vs -0.55% in Mar 2025
YoY Growth in year ended Mar 2026 is 18.64% vs 23.74% in Mar 2025